Literature DB >> 17600395

Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.

Natalie J Carter1, Lesley J Scott.   

Abstract

Haemate P/Humate-P is a pasteurised human plasma-derived concentrate containing coagulation factor VIII and a near-normal spectrum of von Willebrand factor multimers, including high-molecular weight multimers, for intravenous use in patients with von Willebrand disease or haemophilia A. Extensive clinical experience over the past 25 years has shown that Haemate P/Humate-P provides effective haemostatic control for the prevention and treatment of bleeds in patients with these conditions, with no confirmed cases of viral or prion transmission occurring during this time. In small prospective and retrospective noncomparative studies, Haemate P/Humate-P provided effective haemostatic control for the prevention and treatment of bleeding episodes in the vast majority of paediatric and adult patients with von Willebrand disease. Haemate P/Humate-P was generally well tolerated in patients with von Willebrand disease or haemophilia A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600395     DOI: 10.2165/00003495-200767100-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  19 in total

1.  Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.

Authors:  S Lethagen; E Berntorp; I M Nilsson
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

Review 2.  Risk of inhibitors in haemophilia and the type of factor replacement.

Authors:  Jenny Goudemand; Yves Laurian; Thierry Calvez
Journal:  Curr Opin Hematol       Date:  2006-09       Impact factor: 3.284

3.  VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Authors:  Suryasarathi Dasgupta; Yohann Repessé; Jagadeesh Bayry; Ana-Maria Navarrete; Bharath Wootla; Sandrine Delignat; Theano Irinopoulou; Caroline Kamaté; Jean-Marie Saint-Remy; Marc Jacquemin; Peter J Lenting; Annie Borel-Derlon; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

4.  Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Authors:  Jenny Goudemand; Chantal Rothschild; Virginie Demiguel; Christine Vinciguerrat; Thierry Lambert; Hervé Chambost; Annie Borel-Derlon; Ségolène Claeyssens; Yves Laurian; Thierry Calvez
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

5.  Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.

Authors:  D Lillicrap; M C Poon; I Walker; F Xie; B A Schwartz
Journal:  Thromb Haemost       Date:  2002-02       Impact factor: 5.249

6.  Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.

Authors:  T Suzuki; M Arai; K Amano; K Kagawa; K Fukutake
Journal:  Thromb Haemost       Date:  1996-11       Impact factor: 5.249

7.  A comparative in vitro evaluation of six von Willebrand factor concentrates.

Authors:  S Lethagen; M Carlson; A Hillarp
Journal:  Haemophilia       Date:  2004-05       Impact factor: 4.287

8.  Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.

Authors:  Massimo Franchini; Gina Rossetti; Annarita Tagliaferri; Corrado Pattacini; Donatella Pozzoli; Giuseppe Lippi; Franco Manzato; Daniela Bertuzzo; Giorgio Gandini
Journal:  Haematologica       Date:  2003-11       Impact factor: 9.941

9.  Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.

Authors:  K Amano; M Arai; K Koshihara; T Suzuki; K Kagawa; Y Nishida; K Fukutake
Journal:  Am J Hematol       Date:  1995-08       Impact factor: 10.047

10.  Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Authors:  Jan Jacques Michiels; Zwi N Berneman; Marc van der Planken; Wilfried Schroyens; Ulrich Budde; Huub H D M van Vliet
Journal:  Blood Coagul Fibrinolysis       Date:  2004-06       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.